<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1387</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2009</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>13</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa>افزایش سمییت داروی سیس پلاتین در سلولهای ملانوما بدنبال فرو تنظیمی بیان پروتئین IAP-ML</title_fa>
	<title>Increased Cytotoxicity of Cisplatin in SK-MEL 28 Melanoma Cells upon Down-Regulation of Melanoma Inhibitor of Apoptosis Protein</title>
	<subject_fa> Related Fields</subject_fa>
	<subject>Related Fields</subject>
	<content_type_fa>مقاله کامل</content_type_fa>
	<content_type>Full Length/Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Background: Malignant melanoma is a highly metastatic cutaneous cancer and typically refractory to chemotherapy. Deregulated apoptosis has been identified as a major cause of cancer drug resistance, and upregulated expression of the inhibitor of apoptosis protein melanom, an inhibitor of apoptosis (ML-IAP) is frequent in melanoma. Methods: Based on the conclusion that ML-IAP expression contributes to a malignant phenotype, we down-regulated the ML-IAP mRNA using sequence optimized antisense oligonucleotides. Results: As measured by real-time PCR, oligonucleotides M706 and M711 inhibited ML-IAP mRNA expression by 47% and 52%, respectively in the highly metastatic and drug resistant SK-MEL28 cell line. Oligonucleotide M706, which was previously evaluated in G361 cells as the most efficient inhibitor of ML-IAP expression, was chosen to compare cell viability and drug sensitivity of these two melanoma cell lines with different p53 functionality. Protein expression was reduced by oligonucleotide M706 to 49% of the normal level and resulted in a dose-dependent specific reduction of cell viability with a maximum of 39% at 600 nM. Typical morphological changes showed that loss of viability was mainly due to cell death. In combination experiments, the use of oligonucleotide M706 resulted in a two-fold increase of cisplatin cytotoxicity at different concentrations of oligonucleotide and cisplatin (P&lt;0.05). This is in line with our previous findings in G361 melanoma cell line, in which oligonucleotide M706 caused a 3-fold increase in cisplatin cytotoxicity. Conclusion: Our data suggest the use of ML-IAP antisense oligonucleotides to overcome drug resistance in metastatic melanoma, in spite of its p53 status.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Melanoma, Melanoma inhibitor of apoptosis (ML-IAP, Livin), Cytotoxicity, Antisense, Cisplatin</keyword>
	<start_page>27</start_page>
	<end_page>34</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-17&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Parisa</first_name>
	<middle_name></middle_name>
	<last_name>Mousavi-Shafaei</last_name>
	<suffix></suffix>
	<first_name_fa>پریسا</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>موسوی شفاعی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mousavi_p@ibb.ut.ac.ir</email>
	<code></code>
	<orcid></orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Abed-Ali</first_name>
	<middle_name></middle_name>
	<last_name>Ziaee</last_name>
	<suffix></suffix>
	<first_name_fa>عبدعلی</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>ضیایی</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Uwe</first_name>
	<middle_name></middle_name>
	<last_name>Zangemeister-Wittke</last_name>
	<suffix></suffix>
	<first_name_fa>Uwe</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Zangemeister-Wittke</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
